A Validated Radiomics T Cell Score Predicts Response to Multi-site SBRT Combined with Pembrolizumab

The clinical utility of immune checkpoint blockade (ICB) is rapidly advancing. Combining ICB with local cytoreductive therapy, specifically with stereotactic body radiotherapy (SBRT), remains an active area of research. However, no prognostic markers exist to identify patients likely to benefit from combined therapy. The degree of T-cell-mediated immunity is a potential biomarker for predicting response to immunotherapy and prior work demonstrates a potential role for radiomics to identify T-cell infiltration from standard computed tomography (CT) imaging.

Source: International Journal of Radiation Oncology * Biology * Physics - July 19, 2019 Category: Radiology Authors: M.C. Korpics, S.R. Bhave, G. Redler, S. Pitroda, J.J. Luke, S.J. Chmura Tags: Oral Abstracts Source Type: research